User: Guest  Login
Title:

MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy.

Document type:
Journal Article
Author(s):
Peeken, Jan C; Asadpour, Rebecca; Specht, Katja; Chen, Eleanor Y; Klymenko, Olena; Akinkuoroye, Victor; Hippe, Daniel S; Spraker, Matthew B; Schaub, Stephanie K; Dapper, Hendrik; Knebel, Carolin; Mayr, Nina A; Gersing, Alexandra S; Woodruff, Henry C; Lambin, Philippe; Nyflot, Matthew J; Combs, Stephanie E
Abstract:
PURPOSE: In high-grade soft-tissue sarcomas (STS) the standard of care encompasses multimodal therapy regimens. While there is a growing body of evidence for prognostic pretreatment radiomic models, we hypothesized that temporal changes in radiomic features following neoadjuvant treatment ("delta-radiomics") may be able to predict the pathological complete response (pCR). METHODS: MRI scans (T1-weighted with fat-saturation and contrast-enhancement (T1FSGd) and T2-weighted with fat-saturation (T2FS)) of patients with STS of the extremities and trunk treated with neoadjuvant therapy were gathered from two independent institutions (training: 103, external testing: 53 patients). pCR was defined as <5% viable cells. After segmentation and preprocessing, 105 radiomic features were extracted. Delta-radiomic features were calculated by subtraction of features derived from MRI scans obtained before and after neoadjuvant therapy. After feature reduction, machine learning modeling was performed in 100 iterations of 3-fold nested cross-validation. Delta-radiomic models were compared with single timepoint models in the testing cohort. RESULTS: The combined delta-radiomic models achieved the best area under the receiver operating characteristic curve (AUC) of 0.75. Pre-therapeutic tumor volume was the best conventional predictor (AUC 0.70). The T2FS-based delta-radiomic model had the most balanced classification performance with a balanced accuracy of 0.69. Delta-radiomic models achieved better reproducibility than single timepoint radiomic models, RECIST or the peri-therapeutic volume change. Delta-radiomic models were significantly associated with survival in multivariate Cox regression. CONCLUSION: This exploratory analysis demonstrated that MRI-based delta-radiomics improves prediction of pCR over tumor volume and RECIST. Delta-radiomics may one day function as a biomarker for personalized treatment adaptations.
Journal title abbreviation:
Radiother Oncol
Year:
2021
Journal volume:
164
Pages contribution:
73-82
Fulltext / DOI:
doi:10.1016/j.radonc.2021.08.023
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/34506832
Print-ISSN:
0167-8140
TUM Institution:
Institut für Allgemeine Pathologie und Pathologische Anatomie; Institut für Diagnostische und Interventionelle Radiologie; Klinik und Poliklinik für Orthopädie und Sportorthopädie; Klinik und Poliklinik für RadioOnkologie und Strahlentherapie
 BibTeX